KUALA LUMPUR: Duopharma Biotech Bhd has reported a sharp rise in profitability for the first half of 2026, with net profit climbing to RM60.59 million from RM45.84 million in the same stretch a year earlier.
The pharmaceutical manufacturer credited the jump to an improved product mix, a stronger ringgit that lowered input expenses, and sustained operational gains. Revenue, however, dipped marginally to RM482.24 million from RM484.52 million. That slight decline stemmed from insulin sales to the public sector returning to normal levels after an unusual spike during the first half of FY25.
Second quarter results showed similar momentum. Net profit for the three months ended June 30, 2026 rose to RM29.87 million from RM20.2 million a year prior. Quarterly revenue also expanded to RM234.36 million versus RM221.78 million.
Shareholders will receive an interim dividend of 1.5 sen per share. The entitlement date falls on Sept 4, 2026, with payment scheduled for Sept 21, 2026.
Looking ahead, the company said its order book remains healthy and its revenue base diversified across public and private healthcare channels. That foundation, management noted, positions it well for the remainder of the financial year.
Still, executives flagged potential headwinds. Geopolitical shifts and global trade friction could keep energy prices, currency movements, and active pharmaceutical ingredient costs volatile.
Group CEO Wan Amir-Jeffery Wan Abdul Majid said the firm would lean on operational discipline, tight cost controls, and supply chain resilience. That includes diversifying API sources and managing inventory with closer supplier coordination. Barring unforeseen disruptions, the group expects a satisfactory full year performance through Dec 31, 2026.
